Space station will host stem cells for heart research – Emory News Center
|
Space station will host stem cells for heart research
Emory News Center Researchers at Emory University School of Medicine and Children’s Healthcare of Atlanta have been using space-simulation machines to enhance the ability of pluripotent stem cells to turn into cardiac muscle cells. Now they – or the cells they’ve … |
|
Space station will host stem cells for heart research
Emory News Center Researchers at Emory University School of Medicine and Children’s Healthcare of Atlanta have been using space-simulation machines to enhance the ability of pluripotent stem cells to turn into cardiac muscle cells. Now they – or the cells they’ve … |
|
Space station will host stem cells for heart research
Emory News Center Researchers at Emory University School of Medicine and Children’s Healthcare of Atlanta have been using space-simulation machines to enhance the ability of pluripotent stem cells to turn into cardiac muscle cells. Now they – or the cells they’ve … |
|
Oncologist explains immunotherapy to be used by Hirono for cancer treatment
Hawaii News Now In a video message, Senator Mazie Hirono says she’ll receive immunotherapy for the next three months to treat spots on her thyroid. “Having cancer sucks, but I know that there are people in our country facing major health issues every single day,” she … |
|
Oncologist explains immunotherapy to be used by Hirono for cancer treatment
Hawaii News Now In a video message, Senator Mazie Hirono says she’ll receive immunotherapy for the next three months to treat spots on her thyroid. “Having cancer sucks, but I know that there are people in our country facing major health issues every single day,” she … |
Seeking Alpha |
Emergence Of A Novel Gene Therapy Mechanism: Krystal Biotech
Seeking Alpha Krystal Biotech is entering into clinical trials with two topical gene therapy agents for rare and debilitating dermatological diseases. Strong financials for a new clinical-stage biotech – appears funded through its lead candidate’s Phase III trial … |